Investors focused on the Medical space have likely heard of Teva Pharmaceutical Industries (TEVA - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Teva Pharmaceutical Industries is one of 845 companies in the Medical group. The Medical group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. TEVA is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for TEVA's full-year earnings has moved 3.79% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, TEVA has gained about 21.85% so far this year. At the same time, Medical stocks have gained an average of 2.55%. This means that Teva Pharmaceutical Industries is outperforming the sector as a whole this year.
To break things down more, TEVA belongs to the Medical - Generic Drugs industry, a group that includes 24 individual companies and currently sits at #165 in the Zacks Industry Rank. Stocks in this group have lost about 1.86% so far this year, so TEVA is performing better this group in terms of year-to-date returns.
Investors in the Medical sector will want to keep a close eye on TEVA as it attempts to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Investors focused on the Medical space have likely heard of Teva Pharmaceutical Industries (TEVA - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Teva Pharmaceutical Industries is one of 845 companies in the Medical group. The Medical group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. TEVA is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for TEVA's full-year earnings has moved 3.79% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, TEVA has gained about 21.85% so far this year. At the same time, Medical stocks have gained an average of 2.55%. This means that Teva Pharmaceutical Industries is outperforming the sector as a whole this year.
To break things down more, TEVA belongs to the Medical - Generic Drugs industry, a group that includes 24 individual companies and currently sits at #165 in the Zacks Industry Rank. Stocks in this group have lost about 1.86% so far this year, so TEVA is performing better this group in terms of year-to-date returns.
Investors in the Medical sector will want to keep a close eye on TEVA as it attempts to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on TEVA - FREE